Simpson Thacher represented Certara, Inc. (“Certara”) and an entity affiliated with EQT AB (“EQT”) in connection with a follow-on offering of common stock of Certara. A total of 23,000,000 shares of common stock were sold in the offering, consisting of 4,500,000 shares sold by Certara and 18,500,000 shares sold by EQT and other selling stockholders, inclusive of the underwriters’ full exercise of their option to purchase additional shares. The offering raised approximately $713 million in gross proceeds.
Certara accelerates medicines using proprietary biosimulation software and technology to transform traditional drug discovery and development. Its clients include more than 1,650 global biopharmaceutical companies, leading academic institutions and key regulatory agencies across 61 countries.
The Simpson Thacher team included Bill Brentani, Kelli Schultz, Jonathan Kachiu and Danielle Bembry (Capital Markets); and Jonathan Goldstein, Jonathan Cantor and Scott Grundei (Tax).